Location History:
- Lansing, MI (US) (1999)
- DeWitt, MI (US) (1992 - 2000)
- Belaire, MI (US) (2014)
Company Filing History:
Years Active: 1992-2014
Title: Paul M. Coussens: A Pioneer in Avian Biotechnology
Introduction
Paul M. Coussens, a prominent inventor hailing from DeWitt, Michigan, has made significant contributions to the field of avian biotechnology. With a remarkable portfolio of 13 patents, Coussens has focused his research on developing innovative solutions for vaccine production and diagnostics.
Latest Patents
Coussens' latest patents showcase his expertise and inventive spirit. One noteworthy patent is for an "Immortal Avian Cell Line and Methods of Use," which describes a unique avian cell line capable of supporting the replication of animal or human viruses. This cell line is adapted for animal-product-free growth, making it particularly useful for propagating viruses that serve as live or killed vaccines, as well as for virus isolation and diagnostic assays.
Another significant invention is the "Avian Herpesvirus-A Antigen Precursor Gene." This gene, derived from Marek's Disease Herpesvirus, is around 1.8-1.9 kbp and is found on a DNA fragment approximately 2.35 kbp in size. The gene can be utilized as a building block for vaccines and as a diagnostic hybridization probe to facilitate the preparation of diagnostic test kits for Marek's Disease Herpesvirus through antigen production and subsequent antibody production. Additionally, it holds potential as a source of regulatory elements, such as signal peptides or promoters, for further applications in protein studies.
Career Highlights
Currently, Paul M. Coussens is associated with Michigan State University, where he has leveraged his expertise to enhance research in the field of veterinary and biomedical sciences. His work not only contributes to advancing scientific knowledge but also plays a vital role in public health through vaccine development and disease diagnostics.
Collaborations
Throughout his career, Coussens has collaborated with esteemed colleagues, including Leland F. Velicer and Peter Brunovskis, fostering a rich environment for innovation and discovery. These collaborations have been instrumental in driving forward research initiatives and translating scientific findings into practical applications.
Conclusion
Paul M. Coussens stands as a significant figure in the biotechnology sector, particularly in avian healthcare. With his extensive patent portfolio and continued commitment to research and innovation, Coussens is poised to make an enduring impact on the scientific community and public health initiatives. His inventiveness not only exemplifies the essence of innovation but also provides essential tools for advancing veterinary medicine and disease prevention.